All News

Should we define preclinical SLE as stages rather than using confusing nomenclatures like UCTD, incomplete lupus, etc? - @DrDavidKarp @rheumnow #RNL2024 https://t.co/OjRjdBzJWE

Links:

TheDaoIndex KDAO2011 ( View Tweet)
When should you intervene? We talk about primary and secondary prevention... but what about primordial prevention that targets social determinants of health? - @drdavidkarp #RNL2024 @rheumnow https://t.co/UGAcNFLqZf

Links:

TheDaoIndex KDAO2011 ( View Tweet)
What early biomarkers are specific for SLE? How many will progress to stage 2? Who should we screen? Will patients revert to pre-stage 1? Is progression preventable? @DrDavidKarp on relevant questions we need to ask regarding preclinical stage 1 lupus. #RNL2024 @rheumnow https://t.co/bJPG68WdyE

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Can HCQ prevent SLE? Results of the MONA-LISA study is being analyzed (pts have +ANA and 1-2 SLICC criteria for SLE randomized to PCB or HCQ) - @DrDavidKarp @rheumnow #RNL2024 https://t.co/9yoFXS7wMe

Links:

TheDaoIndex KDAO2011 ( View Tweet)
#RNL2024 @RheumNow @DrDavidKarp Incomplete lupus is heterogeneous term "Stage 2" pre-classification stage as ILE/UCTD Stage 1: non-specific antibodies, dysregulation 2: incomplete features 3: classified, multi-system disease 4: irreversible tissue damage https://t.co/CuLUzSZ24E

Links:

Eric Dein ericdeinmd ( View Tweet)
@reumacia @RheumNow You are absolutely right. The point was not generally used for psoriasis ( not PsA). I was surprised my self 🤕. Here is the slide again by Dr. Armstrong , great talk by the way. Let me know if you want the handout. https://t.co/C11Gkn2jho

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Appreciative inquiry in rheumatology and how to enhance and improve our clinical notes to frame our encounter in a positive manner. @BharatKumarMD #RNL2024 @RheumNow https://t.co/iTXwjUb6tg

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Some takeways from JAK inhibitors in dermatology talk by Bruce Strober. Great talk. #RNL2024 @RheumNow https://t.co/fuRsSnnsha

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Alopecia aerate and JAK Bruce Strober #RNL2024 @RheumNow https://t.co/lGig1Vpf5x

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Examples from the world of dermatology on JAK inhibitor success stories. Bruce storber. #RNL2024 @RheumNow https://t.co/S01lEIqjbR

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dermatology colleagues are using JAKis with success for wide range of dermatological diseases. Note the beauty of this slide with further elaboration on domain inhibition, cool stuff 🤓 Bruce Strober #RNL2024 @RheumNow https://t.co/2yHHcOgTC8

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Allosteric versus active site inhibition by JAK. Never understood this better. Thanks to Bruce Strober. #RNL2024 @RheumNow https://t.co/r9hhHLO5oS

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
JAK safety and malignancy risk. Great talk by kevin Winthrop. #RNL2024 @RheumNow https://t.co/d7WRHJxrpM

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
@BharatKumarMD at #RNL2024 @RheumNow Appreciative Inquiry in Rheumatology 5(ish) steps Dawn (what focus on) -> Discovery (what gives life) -> Dream (what might be) -> Design (what should be) -> Destiny (how can i execute) -> New Dawn - Empathy at center of inquiry https://t.co/gDhXpi94pT

Links:

Eric Dein ericdeinmd ( View Tweet)
JAK toxicity of interest. Eric Ruderman #RNL2024 @RheumNow https://t.co/qdlJFKTUR8

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Unique and selective allosteric mechanism of deucravacitinib. Eric Ruderman #RNL2024 @RheumNow https://t.co/Zm3bYGR9JJ

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Disease activity indices may perform differently in man and women. @lihi_eder #RNL2024 @RheumNow https://t.co/8G1D0pGKe8

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Diagnostic delay in SpA 2.3 years longer delay in diagnosis in women with PsA. @lihi_eder #RNL2024 @RheumNow https://t.co/d9ao8vvpa5

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
I am jealous of the derms who have topical JAKi! Dr. Strober flaunts all the different JAKi he has at his disposal to treat derm diseases #RNL2024 @rheumnow https://t.co/qdMWCSA5I1

Links:

TheDaoIndex KDAO2011 ( View Tweet)
JAK and TYK2 signaling pathways. Eric Ruderman #RNL2024 @RheumNow https://t.co/WxoZGCEL0z

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
×